Background: 10 Transcriptomics data, often referred as RNA-Seq, are increasingly being adopted in 11 clinical practice due to the opportunity to answer several questions with the same data -12 e.g. gene expression, splicing, allele-specific expression even without matching DNA. 13 
Indeed, recent studies showed how RNA-Seq can contribute to decipher the impact of 14 germline variants. These efforts allowed to dramatically improved the diagnostic yield in 15 specific rare disease patient cohorts. Nevertheless, RNA-Seq is not routinely adopted for 16 germline variant calling in the clinic. This is mostly due to a combination of technical noise 17 and biological processes that affect the reliability of results, and are difficult to reduce 18 using standard filtering strategies. 19 20 Results: 21 To provide reliable germline variant calling from RNA-Seq for clinical use, such as for 22 mendelian diseases diagnosis,, we developed SmartRNASeqCaller: a Machine Learning 23 system focused to reduce the burden of false positive calls from RNA-Seq. Thanks to the 24 availability of large amount of high quality data, we could comprehensively train 25 SmartRNASeqCaller using a suitable features set to characterize each potential variant. 26 2/33
The model integrates information from multiple sources, capturing variant-specific 27 characteristics, contextual information, and external sources of annotation. We tested our 28 tool against state-of-the-art workflows on a set of 376 independent validation samples 29 from GIAB, Neuromics, and GTEx consortia. SmartRNASeqCaller remarkably increases 30 precision of RNA-Seq germline variant calls, reducing the false positive burden by 50% 31 without strong impact on sensitivity. This translates to an average precision increase of 32 20.9%, showing a consistent effect on samples from different origins and characteristics. 33 34 Conclusions: 35 SmartRNASeqCaller shows that a general strategy adopted in different areas of applied 36 machine learning can be exploited to improve variant calling. Switching from a naïve 37 hard-filtering schema to a more powerful, data-driven solution enabled a qualitative and 38 quantitative improvement in terms of precision/recall performances. This is key for the 39 intended use of SmartRNASeqCaller within clinical settings to identify disease-causing 40 variants.
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Keywords: 42 RNA-Sequencing, variant calling, machine learning, transcriptomics 43 44 Background 45 Being able to associate genomic variation to phenotypic traits is a long-lasting question 46 and fundamental task for omics data analysis. Massive adoption of next sequencing 47 technologies enabled the discovery of causal links between genetic variants and 48 phenotypes. This is especially true for monogenic mendelian diseases (1, 2) and in most 49 of cancer studies (3-5). On one side, NGS data have been used to elucidate the genetic 50 3/33 origin of many diseases, with successful diagnoses in 41% of cases overall. On the other 51 side, hundreds of cancer driver genes, and thousands of putative cancer-driver mutations 52 have been identified using NGS with important consequences for diagnosis and 53 treatment. 54 Whole-genome sequencing (WGS) and whole-exome sequencing (WES) are commonly 55 adopted both in multicenter studies with thousands of patients (6-8), and increasingly in 56 clinical daily practice (2, (9) (10) (11) . In parallel, initiatives like GTEx (8) showed how RNA-Seq 57 data enriched the picture of genome-phenome relationships, for example defining tissue-58 specific expression and eQTLs. The potential to answer multiple questions 59 simultaneously from RNA-Seq e.g. gene expression, splicing detection, allele specific 60 expression (12-15), jointly with its reduced costs, convinced an increasingly large share 61 of scientists to adopt RNA-Seq in their analyses. 62 Using RNA-Seq to call germline variants can be beneficial in clinical settings, for example 63 for Mendelian and common diseases studies. While RNA-Seq does not require additional 64 laboratory experiments if data are already collected, it can enhance the information from 65 samples without matching DNA (16, 17 (16, 19, 20) . Those workflows rely on a set of hard-filtering rules implying a trade-off 77 between quality and quantity of called variants. Such filtering schemas have a limited 78 ability to capture complex patterns, and to discriminate true germline calls from the rest. 79 In this work, we developed SmartRNASeqCaller, a machine-learning module to 80 accurately predict germline variants from RNA-Seq. It makes use of a Random Forest 81 (RF) model that integrates intrinsic variant features with external annotations. 82 SmartRNASeqCaller then generates a data-driven nonlinear predictor for germline 83 variants, harnessing the power to detect complex feature relationship from a massive 84 high-quality training dataset. With SmartRNASeqCaller we aim to improve existing state-85 of-the-art in discriminating true germline variants from the rest by adopting a more 86 powerful and integrative approach than the hard-filtering strategy used in most of the 87 existing workflows. The overall objective is to minimize the burden of false positive calls 88 from RNA-Seq to call variants with comparable reliability to WGS/WES results. Similar to 89 other biomedical research fields where machine learning techniques are used (21,22), the 90 main novelty of our approach relies on learning complex patterns to discriminate if a given 91 call is a true germline variant. 92 SmartRNASeqCaller can be applied as a standalone module to refine the results from 93 previous variant calling workflows without requiring a full sample re-analysis. In this work, 94 we provide SmarRNASeqCaller as a plugin to the GATK best-practices workflow. This 95 module can be easily integrated into any variant calling workflow, as long as it provides 96 an aligned BAM file, and a VCF file with the variants to be classified. 97 In order to compare the performance of this newly proposed module, we benchmarked 98 the impact of including SmartRNASeqCaller as an additional step after using the GATK 99 best practices workflow against only using the GATK workflow and against SNPiR. We 100 analysed a set of 10 independent high-quality samples from Neuromics consortium (23), 101 as well as on GIAB sample NA12878 (24). We then compared SmartRNASeqCaller 102 5/33 impact when applied to the resulting variants from the GATK best practices pipeline on 103 365 samples from GTEx consortium, collected from 5 tissues from 73 donors. These 104 independent tests serve to confirm the utility of the method in improving germline variant 105 call precision for clinical applications through specific real use-cases. ClippingScore. Second, each variant is processed by a classifier that estimates the 121 likelihood of being a true germline variant e.g. appearing in the genomic DNA. 122 Importantly, this classifier model has been generated using a RF approximation, trained 123 on a set of high-quality matched samples of WGS and RNA-Seq with more than 600'000 124 variants. Samples for the study 126 To train and validate our tool, we processed samples from three high-quality independent 127 datasets. First, we use 20 samples from Neuromics consortium with high-quality 128 matching DNA sequencing data, specifically WGS from blood samples, and RNA-Seq aligned BAM file, which is obtained with the STAR v2.35a aligner and uses GATK 3.6.0 151 for subsequent processing steps (24), and ii) a VCF file with the initial set of candidate 152 variants that will be used as input for SmartRNASeqCaller. 153 GTEx samples were already aligned with TopHat 1.4, thus we used the provided BAM file 154 as input for the variant calling workflow. This difference in the original alignment step 155 represents an opportunity to evaluate the SmartRNASeqCaller performance on data 156 generated following an alternative approach to the one used to train this classifier. (table 1) . We employed a recursive feature elimination strategy with 10 fold cross 174 validation applied on the training variants set (as shown in Figure 1A ) to select the best 175 8/33 feature set for classification. Analysing the results in Figure 1A , we chose 11 features, 176 given that the overall trade-off among average accuracy, accuracy variance, and 177 overfitting potential of the model. With only 11 features, the overall model accuracy is 178 close to the maximum, is quite compact, and is able to generate robust predictions. 179 Importantly, all excluded features fall very close to some selected feature in the tSNE plot 180 in Figure 1B Code availability and execution requirements 227 SmartRNASeqcaller is available at https://github.com/inab/SmartRNASeqCaller. It can be 228 downloaded and executed as a shell script with specific parameters to change its default 229 behaviour, and/or using software containers e.g. dockers, inside a nextflow workflow (29). 230 We expect to guarantee full analysis reproducibility following recommendations around 231 Open Science, Open Data and Open Source. An average run of SmartRNASeqCaller 232 with Nextflow implementation takes 46 minutes, using less than 4 GB RAM with 4 CPUs 233 in parallel.
234

Results
235
Our first goal was to train a reliable model to classify true germline variants using RNA- 236 Seq. Then we validated using three different independent datasets against three SmartRNASeqcaler obtains better precision/recall results than state-of-the-art 241 workflows on fibroblast samples 242 We proceeded to measure the SmartRNASeqCaller performance on variants from 10 243 independent samples from the same Neuromics cohort used for training. We used 244 SmartRNASeqCaller as predictor for all variants considering called variants using WGS 245 as the gold standard. Following broadly adopted practices (19,19,30), we evaluated 246 single nucleotide variants in regions with a minimum coverage of 8 or more RNA-Seq 247 reads to reduce the impact of wrong calls due to the effect of random noise on low-248 coverage areas. 249 We report the precision/recall results for the all available samples (10 for training set and 250 11/33 10 for validation set) in Figure 2 . In the case of SmartRNASeqCaller we reported 251 separately the performance for the training and validation data sets to assess the model 252 robustness and identify potential signs of overfitting. 253 First, the GATK Best practices workflow has an overall good performance in terms of 254 average precision (82.9% ± 3.9%) and recall (78.7% ± 1.4%). Second, the GATK 255 workflow has a better performance than SNPiR for the whole data set when considering 256 average precision and recall with F1 measure (GATK: 0.81 vs SNPiR: 0.66 From Table   257 2). Third, when comparing the performance on the training and validation samples for SmartRNASeqCaller is robust to both tissue-of-origin differences, and alignment 296 algorithm 297 We then assessed SmartRNASeqCaller performance on a large independent cohort from 298 365 GTEx (8) samples with matching WGS data. We chose tissue from 5 tissues that 299 represent most biopsies in clinical settings: Whole Blood, Skin Sun Exposed, Adipose 300 13/33 Subcutaneous, Skeletal Muscle, and Fibroblasts. These tissues have diverse 301 transcriptome complexity and may be a closer representation of datasets used for clinical 302 applications. 303 GTEx v7 data have been aligned using TopHat v1.4, rather than STAR v3.5.1, which we 304 used to align the training set for SmartRNASeqCaller. Thanks to this, we could test how 305 robust SmartRNASeqCaller is to alternative upstream workflows, as aligners present 306 systematic differences between them. This is a particularly challenging dataset since 307 TopHat 1.4 has been shown to have many limitations and artifacts when compared to 308 recent aligners like STAR or Hisat2 (12,31). 309 In Figure 3A Figure 2 is maintained on GTEx data. 313 Indeed, SmartRNASeqCaller improves precision on average by 20.9%, a 6.25 fold 314 greater than the reduction in recall (3.2%). 315 In Figure 3B , we present the precision values separated by tissue and workflow. The 316 median precision values for the TopHat+GATK workflow strongly depend on the tissue of 317 origin, ranging from 61.4% for Whole Blood, to 73.9% for Skeletal Muscle. After the 318 application of SmartRNASeqCaller, the precision levels range increase and are more 319 compact ranging from 85.6% in Whole Blood to 89.1% in Skeletal Muscle samples, 320 reducing dramatically (~50%) the differences between tissues. Similarly to Figure 3B , we 321 present in Figure 3C recall values for tissue of origin and workflow. SmartRNASeqCaller 322 effect is stable across tissues, reducing the sensitivity on average by 3.2% while keeping 323 the average recall between 85%-90% for all analyzed tissues. This is important because 324 we are able to capture much more true germline variants with higher precision that the 325 standard baseline. In this work we developed SmartRNASeqCaller, a random forest model to reliably 333 discriminate true germline variants from the rest using RNA-Seq. SmartRNASeqCaller 334 combines intrinsic variant characteristics, with external annotation sources in a unique 335 model able to reduce the burden of false positive calls from RNA-Seq. 336 We trained our model using more than 600'000 variants from 10 high-quality samples 337 with matching WGS data from Neuromics Consortium. We then validated it against a 338 dataset of 10 independent samples from the same cohort, as well as on an independent GnomAD dataset (26), may limit the use of Opossum into routine clinical practice. 374 Methods evaluation in most of these works is not standardized and is heavily dependent 375 on the annotations used to determine the scope of analysis e.g. gene definitions, 376 inclusion or exclusion of specific regions/SNP type, publicly available gold standard 377 16/33 dataset, etc. There is therefore a need to joint efforts in the community to standardize 378 those efforts including the definition of relevant datasets and metrics. 379 The main driver to develop SmartRNASeqCaller was to obtain the highest reliability for 380 variants called from RNA-Seq experiments for its use in routine clinical practice. For this 381 we focused on improving the precision of the generated variant calls. We first chose to 382 integrate heterogeneous and non-redundant variants features to generate a rich and 383 complex description of each variant. Tools like SNPiR use a similar approach to apply 384 simple filters to exclude variants if characterized by unreliable features, which improved 385 precision compared to baseline. However, a simple filtering strategy is unable to properly 386 exploit the potential of a rich and complex multidimensional space. It can generate a 387 strong tradeoff between precision and sensitivity that can be detrimental for tasks such as 388 diagnosis. For that, we chose to train a Random Forest classifier on more than 600'000 389 variants from 10 samples. We chose Random Forests because it has been previously 390 applied in complex scenarios with many training samples, producing remarkable results in 391 terms of precision and robustness including DNA variant calling (21). We then evaluated 392 SmartRNASeqCaller following standard practices of processing independent samples 393 from different studies to ensure the general usability of this model across a wide variety of 394 samples from different tissues, and different upstream alternative workflows to generate 395 the initial calls sets. 396 Here we show that switching from a naïve hard-filtering schema to a more powerful, data-397 driven solution enabled a qualitative and quantitative improvement in terms of 398 precision/recall. When compared to a SNPiR-like strategies of filtering all variants 399 annotated by some unreliable characteristic, the drastic reduction in recall does not 400 compensate for the improvement in terms of precision. This effect is mostly due to the 401 improvement and expansion of available annotations since the SNPiR publication, as well 402 as to the quality filtering already implemented in the baseline workflow that removes 403 17/33 plenty of unreliable variants from RNA-Seq. 404 SmartRNASeqCaller builds on existing literature for variant calling using RNA-Seq, 405 improving overall performances and trustworthiness of the obtained results. Nevertheless, 406 as noted in (16, 24) , its discovery potential is inherently limited by the nature of RNA-Seq 407 experimental set-ups: there is no hope to detect variants in areas of the genome that are 408 not expressed. Similarly, tissue-specific gene expression can limit the discovery of 409 phenotypic-causing variants as many experiment tend to use easily accessible tissues 410 rather than the affected one. Those accessible tissues might not express the genes of 411 interest for dissecting the genetic causes of the observed phenotype. However, recent 412 results showed that it is possible to obtain reliable mutation profile data of not easy-to-413 reach tissues from other accessible tissues by generating suitable reprogrammed cells 414 (18). How RNA-Seq data is obtained can also directly affect the sensitivity of our method 415 as nonsense variants can be missed as a result of the nonsense-mediated decay 416 mechanisms (33). 417 Despite these factors limiting the scope of potential discoveries from RNA-Seq, they can 418 simultaneously be turned into a powerful filter against noise. Provided that the sequenced 419 tissue is relevant for the studied disease, RNA-Seq variants can limit the focus to those 420 genes that actually are being used by the affected cells, as well as inferring if there are 421 "missing genes" e.g. genes that are normally expressed in the tissue that are not present 422 in the experiment when considering reference datasets. 423 An additional factor contributing towards the divergence between RNA-Seq variants and 424 variants extracted from DNA is the existence of genes in which only one parental allele is 425 expressed (16, 34) . Previous work in this direction suggests that only 5% -10% of human 
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